Organogenesis (NASDAQ:ORGO) Rating Lowered to Hold at Wall Street Zen

Organogenesis (NASDAQ:ORGO) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued on Saturday.

Several other brokerages have also recently weighed in on ORGO. BTIG Research decreased their target price on Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Organogenesis Price Performance

NASDAQ ORGO opened at $3.21 on Friday. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32. The firm has a market capitalization of $412.93 million, a PE ratio of 40.13 and a beta of 1.43. The company’s 50 day simple moving average is $4.23 and its 200 day simple moving average is $4.58.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The firm had revenue of $225.61 million during the quarter, compared to the consensus estimate of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. As a group, equities research analysts forecast that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Buying and Selling at Organogenesis

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the transaction, the director owned 2,565,591 shares in the company, valued at $13,187,137.74. This trade represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 33.00% of the stock is owned by company insiders.

Institutional Trading of Organogenesis

Large investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of Organogenesis in the third quarter valued at $25,000. State of Alaska Department of Revenue acquired a new position in Organogenesis during the third quarter valued at $25,000. Flagship Harbor Advisors LLC purchased a new stake in Organogenesis in the 4th quarter worth about $34,000. Federated Hermes Inc. boosted its position in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after acquiring an additional 2,953 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Organogenesis during the 4th quarter valued at about $57,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis News Roundup

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.